Gilead signs licensing deals for HIV treatment

Gilead Sciences has signed licensing agreements with the Medicines Patent Pool (MPP) and generic companies to provide greater access to HIV treatment bictegravir.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Gilead sued over HIV treatment

9 February 2018 ViiV Healthcare, which was established by major pharma companies, has filed a patent infringement complaint against Gilead Sciences in a case involving an HIV treatment drug.

Africa

Mylan enters MPP agreement over affordable hepatitis C generics

29 November 2016 Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool, a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries.

More on this story

Americas

Gilead sued over HIV treatment

9 February 2018 ViiV Healthcare, which was established by major pharma companies, has filed a patent infringement complaint against Gilead Sciences in a case involving an HIV treatment drug.

Africa

Mylan enters MPP agreement over affordable hepatitis C generics

More on this story

Americas

Gilead sued over HIV treatment

9 February 2018 ViiV Healthcare, which was established by major pharma companies, has filed a patent infringement complaint against Gilead Sciences in a case involving an HIV treatment drug.

Africa

Mylan enters MPP agreement over affordable hepatitis C generics